Production & Sales - Marketing & Sales

Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.

Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada

Puma Biotechnology has entered into an exclusive license agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.

Eusa Pharma acquires iMCD treatment Sylvant for $115m

Biopharmaceutical firm Eusa Pharma has purchased worldwide rights of Sylvant (siltuximab) from Janssen Sciences Ireland for $115m.

Nuvo Pharmaceuticals completes acquisition of revenue-generating products from Aralez

Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.

Opiant and Sanofi sign licensing deal for drinabant

Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO).

Taisho offers to buy BMS’ UPSA consumer health business for $1.6bn

Taisho Pharmaceutical has offered $1.6bn to acquire UPSA consumer health business from Bristol-Myers Squibb (BMS).

Circassia to acquire full US rights of AstraZeneca’s COPD treatment Tudorza

Circassia Pharmaceuticals is set to exercise an option to purchase full US commercial rights of chronic obstructive pulmonary disease treatment, Tudorza (aclidinium), from AstraZeneca.

Crown Laboratories buys select OTC consumer healthcare brands from GSK

Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.